Pro-ficiency Welcomes Markus Saba to Board of Directors

Pro-ficiency, a leading provider of simulation-based training and compliance solutions in life sciences, announced the appointment of Markus Saba to its Board of Directors on April 18, 2024. Saba, a veteran in the pharmaceutical industry, joins the board with over 25 years of experience at Eli Lilly, where he was instrumental in launching and managing major brands such as Prozac, Cymbalta, and Cialis.

Pro-ficiency CEO, Michael Raymer, emphasized the significance of Saba’s appointment, highlighting his extensive experience and strategic insights in global healthcare marketing. Raymer anticipates that Saba’s expertise will be crucial as Pro-ficiency seeks to expand its support for commercial drug development and launch activities.

In addition to his corporate career, Saba has contributed to academia as a professor at UNC Kenan-Flagler Business School and serves as Executive in Residence at the Center for the Business of Health. He expressed his commitment to advancing life sciences through strategic use of technology and expertise, aligning well with Pro-ficiency’s innovative goals.